-
Mashup Score: 1JNCCN 360 - MM - FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma - 4 year(s) ago
By: Jocelyn Solis-Moreira, MS Posted: Thursday, August 6, 2020 On August 5, the U.S. Food and Drug Administration (FDA) approved the antibody drug-conjugate belantamab mafodotin-blmf (Blenrep) for treatment of adults with relapsed or refractory multiple myeloma. Drug eligibility includes patients who have had…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
FDA approves #belantamabmafodotinblmf for relapsed or refractory #myeloma: https://t.co/DdUoXf1R3U #MMSM #JNCCN360 https://t.co/50eHVlU1GU